Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it

Bristol Myers Squibb focuses on specialized medicines in oncology and immunology, and shares sport a

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

A bipartisan group of United States lawmakers has opened national security investigations into wheth

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c

In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.56, marking a +1.81% move fr

At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Bristol Myers Squibb maintains a robust biopharmaceutical portfolio focused on high-stakes oncology

Technical indicators show encouraging signs for the three stocks.

The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.53, representing a +1.52% chan

Bristol Myers Squibb has a big revenue gap to fill, but it seems up to the challenge. Its robust div

The Nasdaq 100 has tripled since 2020, but 10 mega-caps still trade below pre-Covid levels. Who'

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.

Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is up on Wednesday as the company reported promising cl

Elicio shares complete response data for ELI-002 7P in KRAS pancreatic cancer and plans combination

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

#TheMorningFilter #PortfolioRebalance #StockInvesting These value stocks can balance portfolios heav

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it wor

Bristol Myers Squibb Canada (BMS) is pleased to announce an update to the Canadian product monograph

Converging forces are pushing rates higher in 2026. The Iran conflict closed the Strait of Hormuz, s

Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HC

Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3

Multiple myeloma is a complex and incurable blood cancer, characterized by a relentless cycle of rel

Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d

Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented a

Replimune Group (REPL) shares gain on key RP2 & RP1 oncology data presentations at ASCO. Read th

Camzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adole

This approval marks a significant milestone, establishing the Opdivo plus AVD combination as the fir

In turbulent markets, investors turn to dividend-yielding stocks. Here are analyst ratings for high-

Bristol Myers Squibb (NYSE:BMY) today announced positive late-breaking results from the Phase 3 SUCC

Bristol Myers deploys Claude enterprise AI to 30,000 workers as Anthropic stacks enterprise wins aga

Bristol Myers Squibb expands AI efforts through Anthropic and Tempus partnerships as shares edge hig

The collaboration brings together BMS' deep scientific expertise and Anthropic's frontier AI

In times of market turbulence, investors turn to dividend-yielding stocks. Benzinga provides real-ti

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

The US Supreme Court turned away appeals from six pharmaceutical companies seeking to topple the Med

Tempus AI And Bristol Myers Squibb Expand AI-Driven Trial Design Efforts Across Oncology And Alzheim

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision m

Bristol Myers Squibb unveiled a multibillion-dollar partnership with Hengrui Pharma spanning 13 drug

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and h

In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with pl

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook

Robert F. Kennedy Jr. unveiled a federal initiative to curb the overuse of psychiatric medications,

Bristol-Myers Squibb beats Q1 2026 estimates as growth drugs lift revenue, while the legacy portfoli

Investors turn to dividend-yielding stocks during market turbulence. Benzinga's database offers